retatrutide trial news VisualAbstract: reduces body weight by 17.5% in patients with obesity Phase III retatrutide study demonstrates

The terminology is contested, but the underlying observation is not: the metabolic deterioration of neurons, their diminishing capacity to produce and manage energy, appears to be an early and potentially modifiable feature of the disease process, not merely a downstream consequence of it

WD repeat-containing protein 5 (WDR5) was later described as a specific reader for H3Q5ser, which deciphers epigenetic signals to activate neurodevelopment-related genetic programs

Four SGLT2is are currently approved in Europe for T2D treatment in combination with diet, exercise, and lifestyle changes (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin)

JAMA Cardiol 2:10251029 Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, CREDENCE Trial Investigators et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

But sleep is one of the most powerful metabolic tools available